[ET Net News Agency, 3 August 2020] Sino Biopharmaceutical Limited (01177) said
"Rivaroxaban Tablet" (brand name: Qingruixin), a new oral anticoagulant developed by the
group, has obtained drug registration certificate granted by the National Medical Products
Administration of the People's Republic of China and is deemed to have passed the
Consistency of Quality and Efficacy Evaluation for Generic Drugs.
Rivaroxban is an oral drug that is highly selective and directly inhibits coagulation
factor Xa, which interrupts the intrinsic and extrinsic pathways of the blood coagulation
cascade by inhibiting factor Xa, thus inhibiting both thrombin formation and development
of thrombi. Rivaroxban is suitable for preventing and reducing venous thrombosis events
for patients who undergo elective hip or knee replacement surgeries, patients with deep
vein thrombosis or pulmonary embolism, and patients with non-valvular atrial fibrillation,
and has been included in Category B of the National Drug Catalogue for Medical Insurance.
(RC)
|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01177 SINO BIOPHARM
Nominal 
2.570 -0.110 (-4.104%) Others
03/08/2020 17:29
Sino Biopharm (01177) gets drug registration certificate
| Remark: | Real time quote last updated: 16/04/2024 12:00 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service |